Clinical Trial Update: Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA [Phase 4]

View source ↗

Summary

Phase 4 trial update on withdrawal and re-treatment with etanercept in Nr-axial spondyloarthritis (nr-axial SpA) completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Spondyloarthritis

Drugs mentioned

• Etanercept (etanercept)

Snippet

Sponsor: Pfizer | Conditions: Spondylitis, Ankylosing | Phase 4 | Status: COMPLETED | Results posted: 2020-06-16